Takeda v. Dr. Reddy’s Labs: Colcrys® Colchicine Patent Dispute Settled After 1,819 Days
Takeda Pharmaceutical filed suit in Delaware against Dr. Reddy’s Laboratories over five patents covering its branded Colcrys® colchicine 0.6 mg tablets. After nearly five years of litigation, the parties reached a confidential settlement, dismissing the case with prejudice — a resolution that forecloses any re-litigation of the same claims.
Five-Patent Colchicine ANDA Battle Ends in Confidential Settlement
Takeda Pharmaceutical Co., Ltd. filed this Hatch-Waxman infringement action on June 24, 2020 in the District of Delaware before Judge Richard G. Andrews, asserting five U.S. patents — US8093298B2, US8093297B2, US7935731B2, US7964648B2, and US7906519B2 — against Dr. Reddy’s Laboratories, Ltd. and its U.S. subsidiary Dr. Reddy’s Laboratories, Inc. (collectively, DRL). The patents in suit relate to Takeda’s branded Colcrys® product, the FDA-approved formulation of colchicine USP 0.6 mg tablets indicated for gout flares and familial Mediterranean fever.
The action concluded on June 17, 2025, when the parties submitted a joint stipulation of dismissal with prejudice under Federal Rules of Civil Procedure 41(a)(1)(A)(ii) and 41(c), reflecting an underlying confidential settlement agreement. Dismissal with prejudice means neither party may re-file the same claims — effectively a permanent resolution. The court retained jurisdiction to enforce the settlement agreement, a standard mechanism preserving judicial oversight if either party alleges a breach. Each side bears its own attorneys’ fees and costs, suggesting neither party extracted a clear capitulation from the other.
The 1,819-day duration — approximately five years — is consistent with complex multi-patent Hatch-Waxman litigation involving multiple claim constructions and potential validity challenges. The confidential nature of the settlement obscures whether DRL secured a license, an agreed launch date, or simply conceded market exclusivity for the remaining patent term. The public record is silent on royalty rates, market-entry dates, or any product-specific carve-outs, which are the commercially critical variables in generic pharmaceutical settlements of this type.
Filing to Dismissed with Prejudice in 1819 days
Duration — nearly 5 years, well above the median ANDA patent suit timeline
Settled with prejudice: what the dismissal terms mean for both parties
Dismissal with prejudice under Rule 41 forecloses re-litigation
A dismissal with prejudice under Rule 41(a)(1)(A)(ii) is a final adjudication on the merits for preclusion purposes, even though no court judgment on the underlying patent claims was issued. Takeda cannot re-assert the same five patents against DRL for the same generic product, and DRL cannot re-open invalidity counterclaims. The court’s retained jurisdiction clause means disputes about settlement performance go back to Judge Andrews rather than requiring a fresh filing.
Rule 41(a)(1)(A)(ii) — permanent barTakeda secures permanent closure — but terms stay confidential
For Takeda, a with-prejudice dismissal preserves the integrity of its Colcrys® patent estate: DRL cannot later challenge the five asserted patents in this venue on these facts. Whether Takeda extracted royalties or delayed DRL’s market entry is unknown from the public record. The each-party-bears-own-costs provision is neutral and does not signal a fee-shifting victory for either side. Takeda’s position as Colcrys® rights-holder appears commercially intact within the scope of this settlement.
Patent estate preservedDRL’s commercial path to colchicine market remains opaque
DRL’s ANDA-driven challenge is resolved, but the settlement’s confidentiality obscures whether it secured a licensed launch date, agreed to stay off-market until patent expiry, or negotiated some hybrid arrangement. The with-prejudice structure means DRL accepted a permanent resolution — typically consistent with a negotiated market-entry date or royalty-bearing license rather than an outright capitulation. IP professionals tracking DRL’s generic colchicine pipeline should monitor FDA Orange Book and ANDA approval records for launch signals.
Launch terms undisclosedConfidential settlements in ANDA cases carry antitrust scrutiny risk
Hatch-Waxman settlements involving delayed generic entry are subject to Federal Trade Commission review under FTC v. Actavis and its progeny. The confidential nature of this agreement means the market cannot independently assess whether any value transfer occurred. Competing generic manufacturers and payers in the gout treatment space should note that colchicine market dynamics remain partially determined by undisclosed terms — and that five patents remain potentially enforceable against other ANDA filers not party to this settlement.
FTC review risk; five patents still liveFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Takeda Pharmaceutical Co., Ltd. | Company | Global pharmaceutical company — holder of five Colcrys® colchicine patentsSearch in Eureka ↗ |
| Defendant | Dr. Reddy’s Laboratories, Ltd. | Company | Indian generic pharmaceutical manufacturer and its U.S. subsidiary seeking ANDA approval for generic colchicine 0.6 mg tabletsSearch in Eureka ↗ |
| Co-Defendant | Dr. Reddy’s Laboratories, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Camille Y. Turner | Attorney | Counsel for Takeda Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Edgar H. Haug | Attorney | Counsel for Takeda Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Francis DiGiovanni | Attorney | Counsel for Takeda Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Jonathan Herstoff | Attorney | Counsel for Takeda Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Porter F. Fleming | Attorney | Counsel for Takeda Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Thatcher A. Rahmeier | Attorney | Counsel for Takeda Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Faegre Drinker Biddle & Reath LLP | Law Firm | Representing Takeda Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Lana S. Shiferman | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Stephen B. Brauerman | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant law firm | Bayard PA | Law Firm | Representing Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated dismissal language is formulaic but carries significant legal weight. The explicit invocation of Rule 41(a)(1)(A)(ii) — a joint stipulation signed by all parties — rather than a unilateral Rule 41(a)(1)(A)(i) notice confirms both sides actively agreed to finality. The with-prejudice designation converts what would otherwise be a procedural close into a claim-preclusive outcome. Notably, the court’s retained jurisdiction is not automatic under Rule 41 and was deliberately preserved, suggesting the settlement agreement contains performance obligations — likely a license term or launch date — that may require future judicial enforcement.
US8093298B2 and four further patents — colchicine formulation and treatment portfolio
The five asserted patents — US8093298B2, US8093297B2, US7935731B2, US7964648B2, and US7906519B2 — cover colchicine formulations, compositions, and methods of treatment associated with Takeda’s Colcrys® product, the first FDA-approved colchicine product indicated for both acute gout flares and familial Mediterranean fever. The application filing dates (ranging across US12 and US13 series) suggest a cluster of continuation and related filings designed to build overlapping claim coverage around the same core compound and therapeutic use, a common lifecycle management technique in small-molecule pharmaceutical patent strategy.
Colchicine is an ancient alkaloid compound that lost patent protection on the molecule itself decades ago, making formulation-level and method-of-use patents the primary IP barrier to generic competition. Takeda’s multi-patent assertion strategy reflects the commercial importance of Colcrys® in the gout market and the limited claim scope available for a genericized active ingredient. For competitors, the practical risk lies in the interaction between these patents’ claim scopes and any ANDA formulation — even minor differences in excipient profiles or dosing regimens may or may not clear the asserted claims, making independent FTO analysis essential for any prospective colchicine ANDA filer.
Should you run an FTO against the Colcrys® colchicine patent portfolio?
Any pharmaceutical company with an active or prospective ANDA for colchicine USP 0.6 mg tablets — or any colchicine-based oral dosage form — should conduct a freedom-to-operate analysis against all five asserted patents and their family members before filing a Paragraph IV certification. This case demonstrates Takeda’s willingness to assert the full portfolio aggressively and sustain litigation for nearly five years. The settlement does not invalidate any claim, meaning each patent remains a live enforcement risk against non-settling filers.
PatSnap Eureka’s FTO Search Agent can map each of the five patent numbers against your proposed colchicine formulation, flag relevant claim language, and surface related continuations or divisionals that may extend effective exclusivity beyond the asserted patents’ face expiry dates. Eureka also tracks Orange Book listings and litigation history across the colchicine patent family, enabling IP teams to prioritize claim-by-claim design-around analysis and identify prior art that may support future IPR petitions against any of the five patents in suit.
Run a freedom-to-operate analysis on US8093298B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman colchicine and small-molecule ANDA patent cases
Explore related Hatch-Waxman infringement actions involving colchicine and branded small-molecule formulation patents litigated in Delaware District Court.
What this case signals for the pharmaceutical patent IP landscape
Multi-patent Hatch-Waxman suits frequently settle confidentially — but the structure of settlement terms drives real market outcomes.
Five asserted patents signal a layered exclusivity strategy for Colcrys®
Asserting five patents across a single branded small-molecule product is consistent with a lifecycle management approach — staggered expiry dates and overlapping claim scopes create multiple litigation leverage points. Other generic filers facing Colcrys® patents should map each patent’s expiry and claim scope independently before filing an ANDA Paragraph IV certification.
With-prejudice dismissal is not a patent validity ruling — other filers are unaffected
This settlement does not establish any court precedent on validity, infringement, or claim construction for the five asserted patents. Any other generic manufacturer with a pending or future ANDA for colchicine 0.6 mg tablets must independently litigate or design around the same patent estate. The patents remain presumptively valid and enforceable against non-settling parties.
Takeda v Dr. — key questions answered
Takeda asserted five U.S. patents: US8093298B2, US8093297B2, US7935731B2, US7964648B2, and US7906519B2. All relate to Colcrys® (colchicine USP) 0.6 mg tablets. The patents cover formulation compositions and methods of treatment associated with colchicine, a compound used to treat acute gout flares and familial Mediterranean fever.
The case was dismissed with prejudice on June 17, 2025, pursuant to a joint stipulation under Rule 41(a)(1)(A)(ii). The dismissal reflected an underlying confidential settlement agreement between Takeda and DRL. The terms of the settlement — including any license grant, royalties, or market-entry dates — are not disclosed in the public record. Each party bears its own attorneys’ fees and costs.
No. A with-prejudice dismissal by stipulation does not constitute a court ruling on patent validity or infringement and creates no precedent binding on other parties. Any other generic manufacturer with a pending or future ANDA for colchicine 0.6 mg tablets must independently address the five asserted Takeda patents. The patents remain presumptively valid and enforceable against non-settling ANDA filers.
The court explicitly retained jurisdiction to enforce the confidential settlement agreement. This means that if either party alleges the other breached the settlement terms — for example, if DRL launches its generic product before an agreed date — Takeda can seek enforcement directly before Judge Andrews in Delaware without filing a new lawsuit. This is a commercially significant term that provides Takeda a fast-track remedial path.
The case lasted 1,819 days, from filing on June 24, 2020 to closure on June 17, 2025 — approximately five years. This duration is consistent with complex multi-patent Hatch-Waxman litigation involving multiple asserted patents, ANDA-specific discovery, and potential claim construction proceedings, though the public docket does not detail the specific procedural milestones that drove the timeline.
PatSnap Eureka searches patents and litigation data to answer instantly.